Hangzhou Cancer Institute in Hangzhou Cancer Hospital

Hangzhou, China

Hangzhou Cancer Institute in Hangzhou Cancer Hospital

Hangzhou, China
SEARCH FILTERS
Time filter
Source Type

Hassan C.,The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine | Afshinnekoo E.,New York Medical College | Li S.,University of Connecticut Health Center | Wu S.,Hangzhou Cancer Institute in Hangzhou Cancer Hospital | And 2 more authors.
Experimental Hematology | Year: 2017

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy with an exceedingly poor prognosis: a 5-year overall survival rate of 40%-45% in the young and a 5-year survival rate of less than 10% in the elderly (>60 years of age). Although a high percentage of patients enters complete remission after chemotherapeutic intervention, the majority of patients relapse within 3 years. Such stark prognostic outcomes highlight the need for additional clinical research, basic discovery, and molecular delineation of the etiologies and mechanisms behind responses to therapy that lead to relapse. Here, we summarize recent discoveries in tumor heterogeneity at the genetic and epigenetic levels and their independent molecular trajectories and dynamics in response to therapy. These new discoveries may have significant implications for understanding, monitoring, and treating leukemia and other cancers. © 2017 ISEH - Society for Hematology and Stem Cells.


Mason C.E.,The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine | Mason C.E.,Feil Family Brain & Mind Research Institute | Afshinnekoo E.,The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine | Afshinnekoo E.,New York Medical College | And 3 more authors.
Journal of Biomolecular Techniques | Year: 2017

Challenges and biases in preparing, characterizing, and sequencing DNA and RNA can have significant impacts on research in genomics across all kingdoms of life, including experiments in single-cells, RNA profiling, and metagenomics (across multiple genomes). Technical artifacts and contamination can arise at each point of sample manipulation, extraction, sequencing, and analysis. Thus, the measurement and benchmarking of these potential sources of error are of paramount importance as next-generation sequencing (NGS) projects become more global and ubiquitous. Fortunately, a variety of methods, standards, and technologies have recently emerged that improve measurements in genomics and sequencing, from the initial input material to the computational pipelines that process and annotate the data. Here we review current standards and their applications in genomics, including whole genomes, transcriptomes, mixed genomic samples (metagenomes), and the modified bases within each (epigenomes and epitranscriptomes). These standards, tools, and metrics are critical for quantifying the accuracy of NGS methods, which will be essential for robust approaches in clinical genomics and precision medicine. © 2017, Association of Biomolecular Resource Facilities. All rights reserved.

Loading Hangzhou Cancer Institute in Hangzhou Cancer Hospital collaborators
Loading Hangzhou Cancer Institute in Hangzhou Cancer Hospital collaborators